CLOBEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CLOBEX (CLOBEX).
Clobetasol propionate is a corticosteroid with high potency that binds to glucocorticoid receptors, thereby modulating gene expression to inhibit inflammatory mediators (e.g., prostaglandins, leukotrienes) and suppress immune responses. It also induces vasoconstriction and reduces edema.
| Metabolism | Primarily metabolized in the liver via cytochrome P450 3A4 (CYP3A4) to inactive metabolites. |
| Excretion | Primarily renal (minimal biliary/fecal). After topical application, less than 2.5% of the dose is excreted in urine as metabolites. |
| Half-life | The terminal elimination half-life after topical application is approximately 3.7 hours, consistent with rapid systemic clearance of absorbed drug. |
| Protein binding | Clobetasol propionate is approximately 98% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is not well-characterized for topical clobetasol; after systemic absorption, distribution is extensive (approx. 0.4 L/kg based on intravenous data from similar corticosteroids). |
| Bioavailability | Topical bioavailability is <5% of applied dose under normal conditions; occlusive dressing may increase absorption up to 10%. |
| Onset of Action | Onset of therapeutic effect for plaque psoriasis typically occurs within 1–2 weeks of twice-daily topical application. |
| Duration of Action | Duration of action is related to dosing frequency; clinical response is maintained with twice-daily application. Continuous long-term use (beyond 2 weeks) is not recommended due to risk of adverse effects. |
0.05% spray applied to affected area twice daily. Apply twice daily to affected areas of the scalp or body. Do not use more than 2 consecutive weeks or exceed 50 g/week.
| Dosage form | LOTION |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No specific dosage adjustment provided; use caution in severe hepatic impairment due to potential for increased systemic exposure. |
| Pediatric use | Safety and efficacy in pediatric patients below 18 years have not been established. Not recommended for use in children. |
| Geriatric use | No specific dosage adjustment; use with caution due to potential increased skin fragility and systemic absorption in elderly patients. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CLOBEX (CLOBEX).
| Breastfeeding | It is not known if clobetasol is excreted in human milk after topical application. Minimal systemic absorption suggests low risk, but caution is advised. Avoid application to breasts to prevent infant ingestion. No M/P ratio available. |
| Teratogenic Risk | Topical corticosteroids like clobetasol propionate (CLOBEX) are generally considered low risk for teratogenicity when used as directed. Systemic absorption is minimal, but extensive or prolonged use may increase risk. Animal studies show some fetal abnormalities with high systemic doses, but no adequate human studies. First trimester: no known specific risk, but caution advised. Second and third trimesters: avoid prolonged use over large areas. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to clobetasol or any component of formulation","Untreated bacterial, fungal, or viral infections at application site"]
| Precautions | ["Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression","Local adverse reactions including skin atrophy, striae, and telangiectasias","Potential for immunosuppression and increased infection risk","Not for use on face, axillae, or groin unless directed","Avoid prolonged use and occlusive dressings unless necessary"] |
| Food/Dietary | No clinically significant food interactions. However, if used with oral corticosteroids (rare), monitor for increased systemic effects; no dietary restrictions required. |
Loading safety data…
| Fetal Monitoring | Monitor for maternal adrenal suppression, Cushing's syndrome, and hyperglycemia with prolonged use over large areas. No specific fetal monitoring required unless signs of growth restriction or endocrine abnormalities. |
| Fertility Effects | No known effects on fertility from topical use. Systemic absorption minimal; animal studies with high doses show no significant reproductive impact. |
| Clinical Pearls | Clobex (clobetasol propionate) is a super-high potency topical corticosteroid. Limit continuous use to 2 consecutive weeks; do not exceed 50 g/week due to risk of HPA axis suppression. Avoid use on face, groin, axillae, or intertriginous areas. Abrupt discontinuation may cause rebound flare. |
| Patient Advice | Apply a thin layer only to affected areas; do not cover with bandages unless instructed. · Wash hands after application unless treating hands. · Do not use for more than 2 weeks continuously; follow your doctor’s dosing schedule. · Avoid contact with eyes, mouth, and mucous membranes. · Report signs of skin thinning, infection, or worsening rash. · Do not stop abruptly; your doctor may recommend tapering. · Keep out of reach of children and store at room temperature. |